Featured essay
BIOSECURE Act clinical trial vendor selection pharmaModern Catalyst The BIOSECURE Act entered law on December 18, 2025, as Section 881 of the FY 2026 NDAA, marking a structural pivot in how US pharmaceutical sponsors and contract research organizations (CROs) must evaluate vendor risk. The statute restricts US executive agencies…
Read full essay